Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Mild Facial Paresis in a Recipient of Gam-Covid-Vac Vaccine: A Case Report Publisher



Mahmoudi Hamidabad N1 ; Mafi AR2 ; Abolmaali M3
Authors

Source: Clinical Medicine Insights: Case Reports Published:2022


Abstract

Facial paralysis has been reported as a rare side effect of mRNA COVID-19 vaccines. The Gam-COVID-Vac was introduced in August 2020 in Russia. There was no report of facial paralysis in phase I to III clinical trials of the vaccine. To our knowledge, there is no post-marketing report of facial paresis with Gam-COVID-Vac vaccination to this date. The Gam-COVID-Vac vaccine has a reported efficacy of 90%, but its safety and efficacy have not been approved by international organizations to this date. Iran is among the countries using the Gam-COVID-Vac vaccine. Here, we present a case of mild facial paresis that occurred shortly after the Gam-COVID-Vac vaccine administration in a female healthcare worker. © The Author(s) 2022.
Other Related Docs
5. Covid-19 Vaccination and Herpes Zoster, Iranian Journal of Dermatology (2024)
18. Covid-19 Vaccine Hesitancy in Iranian Patients With Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2022)